Previous 10 | Next 10 |
home / stock / teva / teva articles
Friday, Alvotech (NASDAQ:ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd (NYSE:TEVA...
U.S. stock futures were lower this morning, with the Dow futures trading lower by over 50 points on Monday. Shares of Li Auto Inc. (NASDAQ: LI) ro...
As previously speculated, Teva Pharmaceutical Industries (NYSE:TEVA) will not undergo a split into two separate entities. On Tuesda...
U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) rose sharply ...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
U.S. stocks traded mostly lower, with the Nasdaq Composite falling over 200 points on Wednesday. Shares of The Boeing Company (NYSE: BA) rose duri...
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported fourth-quarter 2023 sales of $4.46 billion, beating the consensus of $3.99 billio...
Disappointing tech tidings appear to be weighing down on the market, with the Nasdaq futures diving in early trading on Wednesday while the Dow fut...
The past week’s earnings were bordering on the negative, impacting trader sentiment, and the focus now shifts to the unfolding week that woul...
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Limited American Depositary Shares Company Name:
TEVA Stock Symbol:
NYSE Market:
Teva Pharmaceutical Industries Limited American Depositary Shares Website:
2024-07-10 08:00:08 ET Ashwani Verma from UBS issued a price target of $24.00 for TEVA on 2024-07-10 07:20:00. The adjusted price target was set to $24.00. At the time of the announcement, TEVA was trading at $15.81. The overall price target consensus is at $15.00 with h...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8...
4th interim analysis of PEARL real world migraine prevention study presented at 10th European Association of Neurology (EAN) congress in Helsinki New sub-analysis of PEARL data highlights potential negative impact of treatment pauses on patient outcomes 1 Sub-analysis explorin...